Comanche Biopharma is developing novel siRNA (Small interfering RNA) compounds to treat preeclampsia via gene silencing.
The protein sFLT-1 is believed to be the cause of preeclampsia. This protein, produced by the placenta and measurable in the plasma of pregnant women, is both diagnostic and prognostic for preeclampsia and is causally responsible for its disease manifestations when over-expressed.
Comanche Biopharma is developing conjugated siRNA compounds that accumulate in the placenta where they selectively down-regulate multiple mRNA isoforms coding for sFLT-1 while leaving important angiogenic factors unaffected. By specifically and durably silencing the sFLT-1 gene in the placenta they are able halt production of the protein responsible for preeclampsia.
According to the company, the burden of preeclampsia is substantial and growing in frequency and severity. It results in 10 million patients worldwide with more than 500,000 infant and nearly 80,000 maternal deaths every year.
Subscribe for alerts on new companies featured on Startups.Bio
Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 …
Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and …
Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases. The company engages in the discovery and development of novel therapies that …
Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by …
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …
Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation …
